Original news and analysis on international IP policy
The Trump administration yesterday made some firm statements about reducing health care and drug prices for American consumers and making costs more transparent. The statements again appear to focus on other countries paying more for US-made drugs but also promote generic drugs.
The United States Patent and Trademark Office (USPTO) released a report on 11 February showing an increase in US patents that include at least one woman inventor from 7 percent in the 1980s to 21 percent by 2016. This is still a “small minority” of patented inventors, the report finds, and suggests that it indicates an “underutilisation” of women’s innovative potential.
The leading United States industry association yesterday released its annual International Intellectual Property Index, ranking countries on their progress in protecting US intellectual property rights. The ranks show the US advancing in the area of patent protection, while retaining the top overall score; India strengthening IP and charting a course for other developing countries; and EU countries dominating the higher scoring bracket with Singapore first on patent protection.
President Donald Trump gave the US Congress a rosy, nationalistic presentation of the condition of the US economy and security last night and amid the range of issues raised, mentioned intellectual property twice in the context of trade, and extensively discussed lowering drug prices.
The Trump administration is taking the US intellectual property enforcement coordinator's role in new directions, building on past administrations but trying to address ways it has not been effective in the past, according to the annual report of the coordinator, released yesterday.
A new chapter begins. The business of technology and science has been, and will increasingly be, the business of government: with this in mind, the US Government Accountability Office (GAO) has launched a new Science, Technology Assessment and Analytics (STTA) team with the aim to expand the support to lawmakers on topics whose importance has exponentially increased in the world of today.
Open access advocates in the United States are celebrating the expiration, and non-renewal, of the Copyright Term Extension Act, which introduces into the public domain all works from 1923, and signals an end of the practice by US lawmakers to continually extend the terms of copyright protection.
Leading figures from groups such as Creative Commons and Wikimedia Foundation gathered to discuss why this shift in policy took place, and what it means for the public domain. They asserted that this change is the result of a general acceptance of the value of “the commons,” brought on in part by the era of the internet.
Dean Pinkert writes: The United States Trade Representative (USTR) has been open about its view of the difficulties faced by US companies who claim – generally anonymously – that they have been forced to transfer technology to Chinese entities: “The fact that China systematically implements its technology transfer regime in informal and indirect ways makes it ‘just as effective [as written requirements], but almost impossible to prosecute.’” As I explain in this article, I believe such informality is not merely a barrier to prosecutions; it also presents conceptual challenges for US trade negotiators as they attempt to craft effective means to address the concerns of US companies doing business in China.
The US started 2019 with a bang. Its Supreme Court has just announced a major patent decision, and more big developments could arrive in the coming months. Here are some of the top issues to watch this year.
While the World Bank Group and the United Nations Environment Programme (UNEP) are looking for new leaders following the unexpected resignations of their heads, the International Telecommunication Union re-elected its secretary general. The European Patent Office got two new vice-chairs, and the European Organization for Nuclear Research (CERN) a new president, both starting in January. Associations for the creative industry and the pharmaceutical industry also elected new top officials, and lawyers continued to practice firm-hopping.